Zydus Lifesciences buyback 2026: Price raised to ₹1,260

What Zydus Lifesciences announced on May 27

Zydus Lifesciences said on Wednesday, May 27, 2026, that its Buyback Committee approved changes to the company’s ongoing share buyback programme. The revision increases the buyback price while reducing the maximum number of equity shares to be repurchased. The company communicated the changes through an exchange filing. Despite the higher price, the overall buyback outlay has not been increased. The buyback will continue to be carried out through the tender offer route.

Buyback price raised to ₹1,260 per share

The buyback price has been revised upward to ₹1,260 per equity share. Earlier, the company had announced a buyback price of ₹1,150 per share. This change means eligible shareholders who tender shares in the buyback would be offered a higher price per share than initially proposed. The decision was approved by the Buyback Committee at its meeting held on May 27, 2026.

Number of shares reduced to 87.30 lakh

Alongside the price increase, Zydus Lifesciences reduced the maximum number of shares it plans to buy back. The revised proposal is to repurchase up to 87,30,158 equity shares (about 87.30 lakh shares). Earlier, the proposed maximum was 95,65,217 equity shares (about 95.65 lakh shares). The revised share count represents up to 0.87% of the company’s total paid-up equity share capital, as stated in the filing. This compares with the earlier disclosure that the buyback covered approximately 0.95% of the paid-up equity share capital.

Total buyback size stays capped at ₹1,100 crore

Zydus Lifesciences said the aggregate amount for the buyback remains unchanged at up to ₹1,100 crore. In other words, the company is keeping the maximum cash outflow constant, even after raising the buyback price. The reduction in the maximum number of shares aligns the share count with the unchanged monetary cap at the higher per-share price. The company also disclosed earlier that the buyback amount represented 5.16% and 3.84% of the aggregate paid-up equity capital and free reserves.

Tender offer route: how the buyback will be executed

The company said the buyback will be conducted via the tender offer route under SEBI rules. Under this method, eligible shareholders can offer (tender) their shares to the company during the buyback window, subject to the terms and acceptance levels set out in the offer. The exchange communication reiterates that the programme is structured as a tender offer rather than open market purchases.

Record date set for May 29, 2026

Zydus Lifesciences has set May 29, 2026 (Friday) as the record date for the buyback, as cited in the provided details. The record date is used to determine which shareholders are eligible to participate. Investors who hold the company’s shares in their demat accounts as of the record date are generally considered eligible to tender shares in the buyback, based on the rules and final offer documents.

What was announced earlier in May

Zydus Lifesciences had earlier approved a buyback of up to 95,65,217 equity shares at a price of ₹1,150 per share, with the total buyback size capped at ₹1,100 crore. The company also stated that each equity share has a face value of ₹1. A separate timeline reference cited May 19 as the date when the company announced an equity buyback for 9,565,217 shares representing 0.95% for ₹1,100 crore (₹11,000 million), consistent with the same overall cap.

Key buyback parameters after the revision

The updated details disclosed by the company are summarised below.

What changed: a quick before-and-after snapshot

The revision is focused on two levers: price and maximum share count, while leaving the total outlay unchanged.

Why the revision matters for shareholders and the market

For shareholders evaluating whether to participate, the revised price is the most direct change because it sets the offer level for shares tendered in the buyback. At the same time, the lower maximum share count implies a smaller pool of shares that can be accepted under the offer compared with the earlier plan, all else equal. The revision also signals that the company is maintaining the same total cash allocation for the buyback programme, rather than expanding the size of the capital return.

Conclusion

Zydus Lifesciences has revised its buyback terms by raising the repurchase price to ₹1,260 per share and reducing the maximum shares to 87,30,158, while keeping the buyback size capped at ₹1,100 crore. The company will execute the buyback through the tender offer route, with May 29, 2026 set as the record date. The next key milestones for investors will be the buyback offer timeline and detailed participation terms released through formal filings and offer documents.